PM-pathway control state: Difference between revisions
From Bioblast
Beno Marija (talk | contribs) No edit summary |
Beno Marija (talk | contribs) No edit summary |
||
Line 5: | Line 5: | ||
'''MitoPathway control state:''' N | '''MitoPathway control state:''' N | ||
'''SUIT protocol:''' [[ | '''SUIT protocol:''' [[1PM;2D;3U;4G;5S;6Oct;7Rot;8Gp-]] - SUIT_RP1 | ||
[[Pyruvate]] (P) is oxidatively decarboxylated to acetyl-CoA and CO<sub>2</sub>, yielding [[NADH]] catalyzed by pyruvate dehydrogenase. [[Malate]] (M) is oxidized to oxaloacetate by mt-malate dehydrogenase located in the mitochondrial matrix. Condensation of oxaloacate with acetyl-CoA yields citrate (citrate synthase). 2-oxoglutarate (α-ketoglutarate) is formed from isocitrate (isocitrate dehydrogenase). | [[Pyruvate]] (P) is oxidatively decarboxylated to acetyl-CoA and CO<sub>2</sub>, yielding [[NADH]] catalyzed by pyruvate dehydrogenase. [[Malate]] (M) is oxidized to oxaloacetate by mt-malate dehydrogenase located in the mitochondrial matrix. Condensation of oxaloacate with acetyl-CoA yields citrate (citrate synthase). 2-oxoglutarate (α-ketoglutarate) is formed from isocitrate (isocitrate dehydrogenase). | ||
Line 15: | Line 15: | ||
[[File:PM.jpg|right|400px|link=Gnaiger 2014 MitoPathways |Gnaiger 2014 MitoPathways - Chapter 3.2]] | [[File:PM.jpg|right|400px|link=Gnaiger 2014 MitoPathways |Gnaiger 2014 MitoPathways - Chapter 3.2]] | ||
== PM<sub>''L''</sub> == | == PM<sub>''L''</sub> == | ||
::::* [[ | ::::* [[1PM;2D;3U;4G;5S;6Oct;7Rot;8Gp-]]: '''<U>1PM</U>''' 2D&Dc (&DcNADH) 3U 4Oct 5G 6S 7Rot 8Gp 9Ama 10Tm 11Azd | ||
== PM<sub>''P''</sub> == | == PM<sub>''P''</sub> == | ||
::::* [[ | ::::* [[1PM;2D;3U;4G;5S;6Oct;7Rot;8Gp-]]: 1PM '''<U>2D</U>'''&Dc (&DcNADH) 3U 4Oct 5G 6S 7Rot 8Gp 9Ama 10Tm 11Azd | ||
== PM<sub>''E''</sub> == | == PM<sub>''E''</sub> == | ||
::::* [[ | ::::* [[1PM;2D;3U;4G;5S;6Oct;7Rot;8Gp-]]: 1PM 2D 2c (2NADH) '''<U>3U</U>''' 4Oct 5G 6S 7Rot 8Gp 9Ama 10Tm | ||
Revision as of 12:24, 22 January 2018
Description
MitoPathway control state: N
SUIT protocol: 1PM;2D;3U;4G;5S;6Oct;7Rot;8Gp- - SUIT_RP1
Pyruvate (P) is oxidatively decarboxylated to acetyl-CoA and CO2, yielding NADH catalyzed by pyruvate dehydrogenase. Malate (M) is oxidized to oxaloacetate by mt-malate dehydrogenase located in the mitochondrial matrix. Condensation of oxaloacate with acetyl-CoA yields citrate (citrate synthase). 2-oxoglutarate (α-ketoglutarate) is formed from isocitrate (isocitrate dehydrogenase).
Abbreviation: PM
Reference: Gnaiger 2014 MitoPathways - Chapter 3.2
MitoPedia concepts:
SUIT state
PML
- 1PM;2D;3U;4G;5S;6Oct;7Rot;8Gp-: 1PM 2D&Dc (&DcNADH) 3U 4Oct 5G 6S 7Rot 8Gp 9Ama 10Tm 11Azd
PMP
- 1PM;2D;3U;4G;5S;6Oct;7Rot;8Gp-: 1PM 2D&Dc (&DcNADH) 3U 4Oct 5G 6S 7Rot 8Gp 9Ama 10Tm 11Azd
PME
- 1PM;2D;3U;4G;5S;6Oct;7Rot;8Gp-: 1PM 2D 2c (2NADH) 3U 4Oct 5G 6S 7Rot 8Gp 9Ama 10Tm
Linear coupling control in the N-pathway control state: L – P - E
- L - P
- OXPHOS coupling efficiency (P-L or ≈P control factor), j≈P = ≈P/P = (P-L)/P = 1-L/P, is measured in the CI-linked substrate state, with defined coupling sites (CI, CIII, CIV) and at high flux.
- P - E
- CCCP is titrated stepwise to maximum flux, to evaluate limitation of OXPHOS by the phosphorylation system, expressed as the apparent excess E-P capacity factor (E-P coupling control factor), jExP = (E-P)/E = 1-P/E. If jExP>0, then the ET-coupling efficiency rather than the OXPHOS coupling efficiency is the proper expression of coupling, j≈E = ≈E/E = (E-L)/E = 1-L/E.
Discussion
- The Pyruvate anaplerotic pathway control state (pyruvate alone) is not an ET-pathway competent substrate state in most mt-preparations, since acetyl-CoA accumulates without the co-substrate (oxaloacetate) of citrate synthase.
- The Malate anaplerotic pathway control state (M alone) is not an ET-pathway competent substrate state in many mt-preparations, since oxaloacetate accumulates without the co-substrate (acetyl-CoA) of citrate synthase.